[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340132-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340132-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-mettl3-enhances-the-chemosensitivity-of-non-small-cell-lung-cancer-cells-by-decreasing-abcc2-expression-in-an-m6a-ythdf1-dependent-manner","Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner","","Patients with non-small cell lung cancer (NSCLC) often show resistance to first-line chemotherapy using paclitaxel (PTX) or carboplatin (CBP). N6-methyladenosine (m6A) methyltransferase-like 3 (METTL3) regulates m6A modification and contributes to tumorigenesis, yet its role in NSCLC chemoresistance remained unclear. METTL3 inhibition by STM2457 lowered PTX/CBP IC50 values and produced synergistic anti-tumor effects in vitro and in vivo. Mechanistically, targeting METTL3 reduced m6A modification of ABCC2 mRNA, promoted mRNA degradation, and decreased cytomembrane-localized ABCC2 through an m6A-YTHDF1-dependent pathway.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-mettl3-enhances-the-chemosensitivity-of-non-small-cell-lung-cancer-cells-by-decreasing-abcc2-expression-in-an-m6a-ythdf1-dependent-manner/340132/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-mettl3-enhances-the-chemosensitivity-of-non-small-cell-lung-cancer-cells-by-decreasing-abcc2-expression-in-an-m6a-ythdf1-dependent-manner/340132.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does METTL3 inhibition affect PTX and CBP sensitivity in NSCLC cells?","Question",{"text":63,"@type":64},"METTL3 inhibitor STM2457 significantly reduces PTX or CBP IC50 values and shows synergistic anti-tumor effects. Combination treatment with STM2457 plus PTX/CBP produces stronger in vitro and in vivo efficacy than monotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does ABCC2 play in the proposed chemoresistance mechanism?",{"text":68,"@type":64},"ABCC2 is responsively elevated at the cytomembrane after PTX or CBP treatment. Targeting METTL3 reverses this increase by decreasing ABCC2 mRNA m6A modification and accelerating ABCC2 mRNA degradation.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is YTHDF1 important in this METTL3-ABCC2 pathway?",{"text":72,"@type":64},"YTHDF1 binds and stabilizes m6A-modified ABCC2 mRNA. Knockdown of YTHDF1 promotes ABCC2 mRNA degradation, supporting an m6A-YTHDF1-dependent mechanism for enhanced chemosensitivity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340132,1790143444,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2024; 20(12): 4750-4766. doi: 10.7150/ijbs.97425  \nResearch Paper  \nTargeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner  \nRui Zhang1,*, Pu Chen1,*, Yubo Wang1, Zekun Zeng1, Huini Yang1, Mengdan Li2, Xi Liu3,􀀍, Wei Yu1,4,􀀍, Peng Hou1,􀀍  \n1. International Joint Research Center for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P.R. China.  \n2. Department of Cardiology, Xi’an Jiaotong University Second Affiliated Hospital, Xi’an 710061, P.R. China.  \n3. Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710061, P.R. China.  \n4. BioBank, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China.  \n* These authors contributed equally.  \n􀀍 Corresponding authors: Prof. Peng Hou, International Joint Research Center for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi'an 710061, P.R. China; [E-mail: phou@xjtu.edu.cn. Yu Wei](E-mail: phou@xjtu.edu.cn. Yu Wei), PhD, International Joint Research Center for Tumor Precision Medicine of Shaanxi Province and BioBank, The First Affiliated Hospital of Xi’an Jiaotong University, 277 West Yanta Road, Xi'an 710061, P.R. China; [E-mail: yuwei4891@xjtufh.edu.cn. Xi Liu](E-mail: yuwei4891@xjtufh.edu.cn. Xi Liu), MD, PhD, Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, P.R. China; [E-mail: xliu83@xjtu.edu.cn](E-mail: xliu83@xjtu.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.04.17; Accepted: 2024.08.23; Published: 2024.09.03  \nAbstract  \nPatients with non-small cell lung cancer (NSCLC) are easily resistant to first-line chemotherapy with paclitaxel (PTX) or carboplatin (CBP) . N6-methyladenosine (m6A) methyltransferase-like 3 (METTL3) has crucial functions in m6A modification and tumorigenesis. However, its role in chemoresistance of NSCLC is still elusive. Here, we demonstrated that METTL3 inhibitor STM2457 significantly reduced the IC50 values of PTXor CBP in NSCLC cells, and they showed a synergistic effect. Comparing with monotherapy, a combination of STM2457 and PTX or CBP exhibited more potent in vitro and in vivo anti-tumor efficacy. In addition, we found that ATP binding cassette subfamily C member 2 (ABCC2) was responsively elevated in cytomembrane after PTX or CBP treatment, and targeting METTL3 could reverse this effect. Mechanistically, targeting METTL3 decreased the m6A modification of ABCC2 mRNA and accelerated its mRNA degradation. Further studies revealed that YTHDF1 could bind and stabilize the m6A-modified mRNA of ABCC2, while YTHDF1 knockdown promoted it mRNA degradation. These results, taken together, demonstrate that targeting METTL3 enhances the sensitivity of NSCLC cells to PTX or CBP by decreasing the cytomembrane-localized ABCC2 in an m6A-YTHDF1-dependent manner, and suggest that METTL3 may be a potential therapeutic target for acquired resistance to PTX or CBP in NSCLC.  \nKeywords: NSCLC; METTL3; Chemoresistance; ABCC2; m6A; YTHDF1  \nIntroduction  \nLung cancer is the leading cause of cancer mortality among 36 cancer types considered in the worldwide. The approximate number of diagnosed cases was estimated at 236,740 new cases (117,910 in men and 118,830 in women) with 130,180 deaths (68,820 in men and 61,360 in women) in 2022 [1-3] . The most prevalent kind of lung ","cbCaipIgUQ6GmaXf","https://ap.wps.com/l/cbCaipIgUQ6GmaXf","pdf",9628658,17,"English","# Abstract\n# Keywords\n# Introduction\n## Epidemiology of NSCLC and prognosis\n## Chemotherapy in NSCLC: PTX and CBP\n## Mechanisms of chemoresistance and MDR","[{\"question\":\"How does METTL3 inhibition affect PTX and CBP sensitivity in NSCLC cells?\",\"answer\":\"METTL3 inhibitor STM2457 significantly reduces PTX or CBP IC50 values and shows synergistic anti-tumor effects. Combination treatment with STM2457 plus PTX/CBP produces stronger in vitro and in vivo efficacy than monotherapy.\"},{\"question\":\"What role does ABCC2 play in the proposed chemoresistance mechanism?\",\"answer\":\"ABCC2 is responsively elevated at the cytomembrane after PTX or CBP treatment. Targeting METTL3 reverses this increase by decreasing ABCC2 mRNA m6A modification and accelerating ABCC2 mRNA degradation.\"},{\"question\":\"Why is YTHDF1 important in this METTL3-ABCC2 pathway?\",\"answer\":\"YTHDF1 binds and stabilizes m6A-modified ABCC2 mRNA. Knockdown of YTHDF1 promotes ABCC2 mRNA degradation, supporting an m6A-YTHDF1-dependent mechanism for enhanced chemosensitivity.\"}]","Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner | PDF",1790034352,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0708e00d60a99cc7276da3739762ccc1.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e69383c9c94a38e2cbba203e5bb0a8d.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94f821f678dae9c436b869d65501e728.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc256ab713c6da4c130c1525284f2207.webp",980,1268]